Mayne Pharma has completed its $652-million transaction with Teva Pharmaceutical Industries Limited and Allergan, acquiring a portfolio of 42 pharmaceutical products, according to a company statement.
As reported on Reflector.com, the deal was part of the largest generic drug divestiture overseen by the Federal Trade Commission and Mayne Pharma acquired the greatest number of products.
The newly acquired portfolio makes Mayne Pharma the second largest provider of generic oral contraceptives and moves it into the top 25 retail generic pharmaceutical companies in the United States, the release stated.
Officials say the portfolio aligns with the company’s focus on complex pharmaceutical formulations and includes transdermal patches, soft-gel capsules,semi-solids and modified-release capsules and tablets.
Read the full story